Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase NA 2Phase EARLY_PHASE1 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Urologic Neoplasms 1

Interventions

Interleukin-2 3pazopanib 2lenvatinib 2aldesleukin 2Nivolumab 2Nephrectomy 2Metastasectomy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Fluorodeoxyglucose F18 2Cryosurgery 2Biopsy 2tremelimumab 1spartalizumab 1pembrolizumab 1gallium 68 PSMA-11 1enzalutamide 1denileukin diftitox 1daratumumab 1clevudine 1canakinumab 1cabozantinib 1Sorafenib 1Microscopy, Electron 1Isoflavones 1Immunoglobulin G 1Genistein 1FS 069 1FAPI-46 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Renal Cell × Nephrectomy × Clear all
NCT03473730 2025-01-30

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
17 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

NCT02885649 2021-09-16

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Terminated
3 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡